Cover Image
QR Code

Upcoming therapies for heart failure.

Treatment of maladaptive neurohormonal activation in congestive heart failure (CHF) has been successful because basic cardiovascular science findings have been confirmed or dismissed through the use of well-controlled, large-scale clinical trials. It should be no surprise that this exciting approach...

Full description

Published in:Clinical Cornerstone Vol. 3; no. 2; pp. 36 - 48
Main Authors: O'Brien TX, Brown AM
Format: CEU exam questions tables/charts Journal Article
Published: Excerpta Medica Publishing Group 2000
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107014997&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 107014997
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10983597
        YW7
      jtl: Clinical Cornerstone
      issn: 10983597
      maglogo: N
    pubinfo:
      dt: 2000
      vid: 3
      iid: 2
      pid: 1688
      pub: Excerpta Medica Publishing Group
    artinfo:
      ui:
        107014997
        107014997
        2001033178
        NLM11205723
        107014997
      ppf: 36
      ppct: 12
      formats:
      tig:
        atl: Upcoming therapies for heart failure.
      aug:
        au:
          O'Brien TX
          Brown AM
        affil: Asociate Professor of Medicine, Cardiology Section of the Dept of Medicine, Gazes Cardiac Research Institute, Medical University of South Carolina, Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC
      sug:
        subj:
          Heart Failure Drug Therapy
          Antihypertensive Agents Therapeutic Use
          Vasoconstrictor Agents Therapeutic Use
          Tumor Necrosis Factor Therapeutic Use
          Peptides Therapeutic Use
          Cardiac Pacing, Artificial
          Heart Failure Therapy
          Education, Continuing (Credit)
      ab: Treatment of maladaptive neurohormonal activation in congestive heart failure (CHF) has been successful because basic cardiovascular science findings have been confirmed or dismissed through the use of well-controlled, large-scale clinical trials. It should be no surprise that this exciting approach is evolving toward novel agents and devices directed toward other pathways involved in CHF neurohormonal/cytokine activation. Several of these are in advanced clinical development and are likely to play prominent roles in CHF therapy in the near future.
      pubtype: Academic Journal
      doctype:
        CEU
        exam questions
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N